ADMA Biologics Inc (ADMA) vs Trevi Therapeutics, Inc. (TRVI)
ADMA Biologics Inc and Trevi Therapeutics, Inc. are both Biotechnology companies. ADMA Biologics Inc and Trevi Therapeutics, Inc. are of similar size ($2.1B and $2.1B). Trevi Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; ADMA Biologics Inc trades at 13.0×. ADMA Biologics Inc has the higher net margin (33.0% vs 0.00%) and the higher return on invested capital (29.8% vs −1,412.1%). Across the 14 metrics below, ADMA Biologics Inc leads on 11 and Trevi Therapeutics, Inc. on 3.
Valuation
Profitability
| Metric | ADMA | TRVI | Biotechnology median |
|---|---|---|---|
| Gross margin | 64.71% | 0.00% | 65.16% |
| Operating margin | 43.82% | 0.00% | 0.00% |
| Net margin | 32.98% | 0.00% | 0.00% |
| Free cash flow margin | 22.69% | 0.00% | 0.00% |
| Return on equity | 41.90% | (19.66%) | (57.72%) |
| Return on assets | 27.19% | (18.97%) | (49.22%) |
| Return on invested capital | 29.78% | (1,412.11%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack